Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/111—Aromatic compounds
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K10/00—Animal feeding-stuffs
  • A23K10/40—Mineral licks, e.g. salt blocks
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/116—Heterocyclic compounds
  • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/116—Heterocyclic compounds
  • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/184—Hormones
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/195—Antibiotics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K50/00—Feeding-stuffs specially adapted for particular animals
  • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K10/00—Animal feeding-stuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• Ammonia is the most abundant alkaline gas in the atmosphere. In addition, it is a major component of total reactive nitrogen. Recent studies have indicated that ammonia emissions have been increasing over the last few decades on a global scale. This is a concern because ammonia plays a significant role in the formation of atmospheric particulate matter, visibility degradation and atmospheric deposition of nitrogen to sensitive ecosystems. Thus, the increase in ammonia emissions negatively influences environmental and public health. Bovines, and particularly cattle, are major emitters of ammonia. Ammonia is generated and emitted by bovines during their digestive process, as well as emitted from bovine wastes as they break down.
• U.S. Patent No. 6,730,792 discloses lubabegron and salts thereof for use in treating Type II diabetes and obesity and for binding to and activating the ⁇ 3 receptor. Additionally, '792 states that in non-human, non-companion animals, the compounds of formula I described therein are useful for increasing weight gain and/or improving the feed utilization efficiency and/or increasing lean body mass and/or decreasing birth mortality rate and increasing post/natal survival rate. However, lubebagron or salts thereof was not known to reduce ammonia emissions from bovine.
• the present invention provides a method of reducing ammonia emissions from a bovine in need thereof comprising orally administering to the bovine lubabegron, or a physiologically acceptable salt thereof.
• Another aspect of the present disclosure provides lubabegron, or a
• physiologically acceptable salt thereof for use in reducing ammonia emissions from a bovine.
• Another aspect of the present disclosure provides lubabegron, or a physiologically acceptable salt thereof, for use in reducing ammonia emissions from a bovine wherein said lubabegron is to be orally administered.
• bovine feed additive which comprises lubabegron, or a physiologically acceptable salt thereof, and a suitable carrier therefor, wherein said additive is for the reduction of emissions.
• Another aspect of the present disclosure provides an animal feed for reducing ammonia emissions from a bovine which comprises a bovine feed and lubabegron, or a physiologically acceptable salt thereof.
• Lubabegron or a physiologically acceptable salt thereof, such as lubabegron fumarate, may be made by processes known in the art.
• the hemifumarate salt of lubabegron is known as lubabegron fumarate (CAS Registry Number 391926-19-5).
• lubabegron fumarate CAS Registry Number 391926-19-5.
• the processes described in U.S. Patent No. 6,730,792 are illustrative processes that may be used to make lubabegron, or a physiologically acceptable salt thereof.
• the term "bovine” refers to an animal that is a member of the biological subfamily Bovinae, including but not limited to cows/cattle, bison, African buffalo, and water buffalo. In preferred embodiments, the animal is a cow.
• the term “cow” is a bovine of either sex or age, and is a member of the biological genus Bos, including the species Bos taurus and Bos indicus. Cows in a group are commonly known as cattle. As such, the term cow includes dairy cattle, beef cattle, bulls, heifers, oxen, and steers.
• reducing ammonia emissions from a bovine refers to reducing emitted ammonia gas relative to a bovine not treated with lubabegron, or a physiologically acceptable salt thereof.
• the reduction is from about 10 to about 30% in ammonia emissions when compared to an untreated animal.
• the reduction is from about 15 to about 25% in ammonia emissions.
• the reduction of ammonia emissions from a bovine does not significantly negatively affect the bovine, such as, for example, lowering body weight, or decreasing meat and eating quality.
• the reduction is per pound of live weight of the bovine. Live weight means the weight of the bovine while alive.
• the reduction is per pound of hot carcass weight of the bovine.
• Hot carcass weight is the weight of a bovine carcass prior to chilling with its hide, head, gastrointestinal tract, and internal organs removed.
• the reduction of ammonia is accompanied by an increase in hot or live carcass weight.
• the bovine is in confinement for slaughter when administered lubabegron, or a physiologically acceptable salt thereof.
• Lubabegron, or a physiologically acceptable salt thereof can be formulated for oral administration, and such formulations include animal feeds and feed additives.
• the administration is carried out by including lubabegron, or a physiologically acceptable salt thereof, in an animal (bovine) feed.
• the animal feed may be a dry feed or a liquid feed, and includes a bovine' s drinking water containing lubabegron, or a physiologically acceptable salt thereof.
• Such animal feeds may include lubabegron, or a physiologically acceptable salt thereof, combined or admixed with suitable feedstuffs commonly employed in the feeding of bovines.
• feedstuffs commonly employed include corn meal, corncob grits, soybean meal, alfalfa meal, rice hulls, soybean mill run, cottonseed oil meal, bone meal, ground corn, corncob meal, wheat middlings, limestone, dicalcium phosphate, sodium chloride, urea, distillers dried grain, vitamin and/or mineral mixes, cane molasses or other liquid carriers and the like.
• feedstuffs promote a uniform distribution and administration of lubabegron, or a physiologically acceptable salt thereof.
• lubabegron While a particular embodiment for orally administering lubabegron, or a physiologically acceptable salt thereof, is via daily feed rations, lubabegron, or a physiologically acceptable salt thereof, can be incorporated into salt blocks and mineral licks, as well as being added directly to lick tank formulations or drinking water for convenient oral consumption. Lubabegron, or a physiologically acceptable salt thereof, can also be administered orally by bolus or gavage treatment. In some embodiments, lubabegron, or a physiologically acceptable salt thereof, is provided to a bovine ad libitum (i.e., "at will").
• feed additives which include lubabegron, or a physiologically acceptable salt thereof, and one or more suitable carriers.
• the feed additive may be a dry feed additive or a liquid feed additive.
• the feed additives are formulated such that, when added with other materials, an animal feed is formed which will provide a desired concentration of lubabegron, or a physiologically acceptable salt thereof, in the animal feed, and/or provide the desired dose of lubabegron, or a physiologically acceptable salt thereof, to the bovine upon the bovine' s consumption of the animal feed.
• Premixes are recognized terms in the art for certain feed additives. They may be solid or liquid.
• a mineral premix is a composition which is intended for formation of an animal feed and which comprises desired kinds and amounts of minerals, in particular trace minerals.
• a vitamin premix is a composition which is intended for formation of an animal feed and which comprises desired kinds and amounts of vitamins. Some premixes include both vitamins and minerals.
• feed additives includes premixes such as mineral premixes, vitamin premixes, and premixes which include both vitamins and minerals.
• lubabegron, or a physiologically acceptable salt thereof is administrated to the bovine up to at least 91 days prior to slaughter of the bovine. In some embodiments, lubabegron, or a physiologically acceptable salt thereof, is administrated to the bovine up to at least 14 to 56 days prior to slaughter of the bovine. In some embodiments, the period of administration ends upon the bovine' s slaughter. In another embodiment, the bovine is orally administered lubabegron, or a physiologically acceptable salt thereof, in daily feed rations up to 91 days prior to slaughter.
• an effective amount in the context of a feed additive, refers to the quantity of lubabegron, or a physiologically acceptable salt thereof, included in the animal feed sufficient to reduce ammonia emissions from a bovine, as compared to a bovine untreated with lubabegron, or a physiologically acceptable salt thereof, when the bovine consumes the animal feed.
• lubabegron, or the equivalent of the lubabegron free base of a physiologically acceptable salt thereof is administered in an amount from about 1 mg/day to about 500 mg/day. In some embodiments, lubabegron, or the equivalent of the lubabegron free base of a physiologically acceptable salt thereof, is administered in an amount from about 5 mg/day to about 500 mg/day. In some embodiments, lubabegron, or the equivalent of the lubabegron free base of a physiologically acceptable salt thereof, is administered in an amount from about 10 mg/day to about 400 mg/day.
• the animal feed contains from about 0.5 to about 100 grams of lubabegron, or the equivalent of the lubabegron free base of a
• physiologically acceptable salt thereof per ton of animal feed.
• the animal feed contains from about 0.5 to about 50 grams of lubabegron, or the equivalent of the lubabegron free base of physiologically acceptable salt thereof, per ton of animal feed. In some embodiments, the animal feed contains from about 1 to about 25 grams of lubabegron, or the equivalent of the lubabegron free base of a physiologically acceptable salt thereof, per ton of animal feed. In some embodiments, the animal feed contains from about 1.25 to about 20 grams of lubabegron, or the equivalent of the lubabegron free base of a
• physiologically acceptable salt thereof per ton of animal feed.
• the present disclosure includes the use or inclusion of additional active ingredients.
• the additional active ingredients are one or more selected from the group consisting of monensin, tylosin, and
• lubabegron (L) as 4.5 g/lb of Type A Medicated Article.
• CPEs cattle pen enclosures
• test two cycles of cattle each cycle representing all dose (0, 1.25, 5, and 20 g/ton) and gender (steer and heifer) combinations.
• a cycle refers to a group of 112
• a cohort refers to a group of same gender animals representing each of the 4 doses. Up to 4 cycles are used to provide a total of 4 cohorts per gender.
• g/ton/day (100% dry matter basis). Provide feed and water ad libitum.
• On day 91 collect body weight and load cattle for transport to the slaughter facility.
• On day 92 slaughter the cattle and evaluate the carcass.
• monitor and collect ammonia gas emissions data Measure the ammonia emissions over the treatment period and normalize by body weight (BW) for the period (Days 0-7, 0-14, 0-28, 0- 56, and 0-91) and hot carcass weight (HCW) (Days 0-91) (g of gas/animal; g of gas/lb of live BW; g of gas/lb HCW).

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Polymers & Plastics (AREA)
• Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Zoology (AREA)
• Animal Husbandry (AREA)
• Health & Medical Sciences (AREA)
• Birds (AREA)
• Endocrinology (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Fodder In General (AREA)
• Feed For Specific Animals (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (22)

Applications Claiming Priority (1)

Related Child Applications (3)

Publications (1)

Family

ID=54337414

Family Applications (2)

Family Applications After (1)

Country Status (16)

Families Citing this family (2)

Citations (4)

Family Cites Families (5)

• 2015
  • 2015-10-05 CA CA2996879A patent/CA2996879C/en active Active
  • 2015-10-05 WO PCT/US2015/054040 patent/WO2017061983A1/en not_active Ceased
• 2016
  • 2016-08-26 CA CA2940473A patent/CA2940473A1/en not_active Abandoned
  • 2016-09-21 AR ARP160102869A patent/AR106090A1/es active IP Right Grant
  • 2016-10-03 PL PL16785599T patent/PL3358967T3/pl unknown
  • 2016-10-03 CN CN201680058419.XA patent/CN108366583B/zh active Active
  • 2016-10-03 MX MX2018004138A patent/MX389087B/es unknown
  • 2016-10-03 AU AU2016335960A patent/AU2016335960B2/en active Active
  • 2016-10-03 ES ES16785599T patent/ES2791992T3/es active Active
  • 2016-10-03 EA EA201890444A patent/EA032280B1/ru not_active IP Right Cessation
  • 2016-10-03 BR BR112018005162-4A patent/BR112018005162B1/pt active IP Right Grant
  • 2016-10-03 WO PCT/US2016/055123 patent/WO2017062301A1/en not_active Ceased
  • 2016-10-03 US US15/514,876 patent/US11344047B2/en active Active
  • 2016-10-03 CA CA2995626A patent/CA2995626C/en active Active
  • 2016-10-03 EP EP16785599.8A patent/EP3358967B1/en active Active
  • 2016-10-03 CN CN202210118680.1A patent/CN114365796B/zh active Active
  • 2016-10-03 PT PT167855998T patent/PT3358967T/pt unknown
  • 2016-10-03 JP JP2017532013A patent/JP6276478B2/ja active Active
  • 2016-10-03 NZ NZ739892A patent/NZ739892A/en unknown
• 2018
  • 2018-02-13 ZA ZA2018/00959A patent/ZA201800959B/en unknown
• 2022
  • 2022-04-20 US US17/724,717 patent/US11864567B2/en active Active
• 2023
  • 2023-11-21 US US18/515,987 patent/US20240090533A1/en active Pending

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events